Enterohepatic Circulation of Digitoxin Metabolites in the Dog

Author(s):  
G. Ch. Oliver ◽  
L. A. Santini ◽  
G. Griffin ◽  
R. Ruffy
1975 ◽  
Vol 35 (1) ◽  
pp. 162
Author(s):  
G Charles Oliver ◽  
Luis A Santini ◽  
Gail L Griffin ◽  
Duane Haskell

Reproduction ◽  
1972 ◽  
Vol 28 (1) ◽  
pp. 137-138 ◽  
Author(s):  
P. Carroll ◽  
R. Cox

1988 ◽  
Vol 118 (1) ◽  
pp. 33-38
Author(s):  
Judy D. Ribaya-Mercado ◽  
Zohrab Kassarjian ◽  
Robert M. Russell

2021 ◽  
Vol 22 (4) ◽  
pp. 1780
Author(s):  
Maria Chiara di Gregorio ◽  
Jacopo Cautela ◽  
Luciano Galantini

Bile acids (BAs) are facial amphiphiles synthesized in the body of all vertebrates. They undergo the enterohepatic circulation: they are produced in the liver, stored in the gallbladder, released in the intestine, taken into the bloodstream and lastly re-absorbed in the liver. During this pathway, BAs are modified in their molecular structure by the action of enzymes and bacteria. Such transformations allow them to acquire the chemical–physical properties needed for fulling several activities including metabolic regulation, antimicrobial functions and solubilization of lipids in digestion. The versatility of BAs in the physiological functions has inspired their use in many bio-applications, making them important tools for active molecule delivery, metabolic disease treatments and emulsification processes in food and drug industries. Moreover, moving over the borders of the biological field, BAs have been largely investigated as building blocks for the construction of supramolecular aggregates having peculiar structural, mechanical, chemical and optical properties. The review starts with a biological analysis of the BAs functions before progressively switching to a general overview of BAs in pharmacology and medicine applications. Lastly the focus moves to the BAs use in material science.


Gut Microbes ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 1949095
Author(s):  
Junwei Xiang ◽  
Zhengyan Zhang ◽  
Hongyi Xie ◽  
Chengcheng Zhang ◽  
Yan Bai ◽  
...  

2021 ◽  
pp. 1-26
Author(s):  
Kenta Maegawa ◽  
Haruka Koyama ◽  
Satoru Fukiya ◽  
Atsushi Yokota ◽  
Koichiro Ueda ◽  
...  

Abstract Enterohepatic circulation of 12α-hydroxylated (12αOH) bile acid (BA) is enhanced depending on the energy intake in high-fat diet-fed rats. Such BA metabolism can be reproduced using a diet supplemented with cholic acid (CA), which also induces simple steatosis, without inflammation and fibrosis, accompanied by some other symptoms that are frequently observed in the condition of non-alcoholic fatty liver in rats. We investigated whether supplementation of the diet with raffinose (Raf) improves hepatic lipid accumulation induced by the CA-fed condition in rats. After acclimation to the AIN-93-based control diet, male Wistar rats were fed diets supplemented with a combination of Raf (30 g/kg diet) and/or CA (0.5 g/kg diet) for 4 weeks. Dietary Raf normalised hepatic triglyceride levels (two-way ANOVA P<0.001 for CA, P=0.02 for Raf, and P=0.004 for interaction) in the CA-supplemented diet-fed rats. Dietary Raf supplementation reduced hepatic 12αOH BA concentration (two-way ANOVA P<0.001 for CA, P=0.003 for Raf, and P=0.03 for interaction). The concentration of 12αOH BA was reduced in the aortic and portal plasma. Raf supplementation increased acetic acid concentration in the caecal contents (two-way ANOVA P=0.001 as a main effect). Multiple regression analysis revealed that concentrations of aortic 12αOH BA and caecal acetic acid could serve as predictors of hepatic triglyceride concentration (R2=0.55, P<0.001). However, Raf did not decrease the secondary 12αOH BA concentration in the caecal contents as well as the transaminase activity in the CA diet-fed rats. These results imply that dietary Raf normalises hepatic lipid accumulation via suppression of enterohepatic 12αOH BA circulation.


Author(s):  
Richard Radun ◽  
Michael Trauner

AbstractNonalcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver disease, increasingly contributing to the burden of liver transplantation. In search for effective treatments, novel strategies addressing metabolic dysregulation, inflammation, and fibrosis are continuously emerging. Disturbed bile acid (BA) homeostasis and microcholestasis via hepatocellular retention of potentially toxic BAs may be an underappreciated factor in the pathogenesis of NAFLD and nonalcoholic steatohepatitis (NASH) as its progressive variant. In addition to their detergent properties, BAs act as signaling molecules regulating cellular homeostasis through interaction with BA receptors such as the Farnesoid X receptor (FXR). Apart from being a key regulator of BA metabolism and enterohepatic circulation, FXR regulates metabolic homeostasis and has immune-modulatory effects, making it an attractive therapeutic target in NAFLD/NASH. In this review, the molecular basis and therapeutic potential of targeting FXR with a specific focus on restoring BA and metabolic homeostasis in NASH is summarized.


Sign in / Sign up

Export Citation Format

Share Document